Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

614 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Racial Differences in Systemic Immune Parameters in Individuals With Lung Cancer.
von Itzstein MS, Liu J, Mu-Mosley H, Fattah F, Park JY, SoRelle JA, Farrar JD, Gwin ME, Hsiehchen D, Gloria-McCutchen Y, Wakeland EK, Cole S, Bhalla S, Kainthla R, Puzanov I, Switzer B, Daniels GA, Zakharia Y, Shaheen M, Zhang J, Xie Y, Gerber DE. von Itzstein MS, et al. Among authors: daniels ga. JTO Clin Res Rep. 2024 Oct 19;6(1):100751. doi: 10.1016/j.jtocrr.2024.100751. eCollection 2025 Jan. JTO Clin Res Rep. 2024. PMID: 39619775 Free PMC article.
Cancer Clinical Trial Participation: A Qualitative Study of Black/African American Communities' and Patient/Survivors' Recommendations.
Kaljee L, Antwi S, Dankerlui D, Harris D, Israel B, White-Perkins D, Aboah VO, Aduse-Poku L, Larrious-Lartey H, Brush B, Coombe C, Patman L, Cawthorne N, Chue S, Rowe Z, Mills C, Fernando K, Daniels G, Walker EM, Jiagge E. Kaljee L, et al. Among authors: daniels g. JNCI Cancer Spectr. 2024 Nov 25:pkae119. doi: 10.1093/jncics/pkae119. Online ahead of print. JNCI Cancer Spectr. 2024. PMID: 39585656
Combined PD-1 and CTLA-4 Blockade in an International Cohort of Patients with Acral Lentiginous Melanoma.
McGillivray E, Ashouri K, Chatziioannou E, Gallegos JAO, Zarka J, Kechter J, Hwang AS, Zhang K, Barros M, Yeh J, Okazaki I, Crocker AB, Maeda T, Park SJ, Choi J, Andreoli M, Darwish T, Savage DJ, Kim KB, Gupta J, Shen J, Shirai K, Choi A, Pai L, de Lima Vazquez V, Moser J, Amaral T, Hernandez Aya LF, Lutzky J, Najjar YG, Costello CM, Mangold AR, Bhatia S, Gibney GT, Farma JM, Daniels GA, Sosman J, Chandra S, Mangla A, Bollin K, Abrão Possik P, Robles Espinoza CD, Ito F, In GK. McGillivray E, et al. Among authors: daniels ga. Br J Dermatol. 2024 Oct 23:ljae401. doi: 10.1093/bjd/ljae401. Online ahead of print. Br J Dermatol. 2024. PMID: 39438074
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, Queirolo P, Dummer R, Butler MO, Hill AG, Postow MA, Gaudy-Marqueste C, Medina T, Lao CD, Walker J, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Sandhu S, Lebbé C, Ascierto PA, Long GV, Ritchings C, Nassar A, Askelson M, Benito MP, Wang W, Hodi FS, Larkin J; CheckMate 067 Investigators. Wolchok JD, et al. N Engl J Med. 2025 Jan 2;392(1):11-22. doi: 10.1056/NEJMoa2407417. Epub 2024 Sep 15. N Engl J Med. 2025. PMID: 39282897 Clinical Trial.
Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab.
Gogas H, Ravimohan S, Datta A, Chhibber A, Couselo EM, Diab A, Pereira C, Quéreux G, Sandhu S, Curti B, Khushalani NI, Taylor MH, Daniels GA, Spreafico A, Meniawy T, Van Den Eertwegh AJM, Sun Y, Arriaga Y, Zhou M, Long GV, Lebbé C. Gogas H, et al. Among authors: daniels ga. NPJ Precis Oncol. 2024 Jul 19;8(1):150. doi: 10.1038/s41698-024-00641-7. NPJ Precis Oncol. 2024. PMID: 39025948 Free PMC article.
614 results